https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-02-16 / Biochem Biophys Res Commun 2023 Apr;653:106-114
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-02-16 / Biochem Biophys Res Commun 2023 Apr;653:106-1142023-02-16 00:00:002023-02-16 00:00:00Anti-TNFR2 enhanced the antitumor activity of a new HMGN1/3M-052 stimulated dendritic cell vaccine in a mouse model of colon cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-02-13 / Cancers (Basel) 2023 Feb;15(4)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-02-13 / Cancers (Basel) 2023 Feb;15(4)2023-02-13 00:00:002023-05-30 16:20:40Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-01-31 / Expert Opin Drug Discov 2023 Jan;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-01-31 / Expert Opin Drug Discov 2023 Jan;2023-01-31 00:00:002023-01-31 00:00:00Glioblastoma treatment slowly moves towards change: novel druggable targets and translational horizons in 2022
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-01-20 / Strahlenther Onkol 2023 Jan;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-01-20 / Strahlenther Onkol 2023 Jan;2023-01-20 00:00:002023-01-20 00:00:00[Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-01-17 / Biomedicines 2023 Jan;11(2)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-01-17 / Biomedicines 2023 Jan;11(2)2023-01-17 00:00:002023-01-17 00:00:00Modification of Breast Cancer Milieu with Chemotherapy plus Dendritic Cell Vaccine: An Approach to Select Best Therapeutic Strategies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-01-09 / Curr Opin Oncol 2023 Mar;35(2):87-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-01-09 / Curr Opin Oncol 2023 Mar;35(2):87-932023-01-09 00:00:002023-01-09 00:00:00Current „state of the art“ on dendritic cell-based cancer vaccines in melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-01-04 / Int J Mol Sci 2023 Jan;24(2)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-01-04 / Int J Mol Sci 2023 Jan;24(2)2023-01-04 00:00:002023-01-04 00:00:00Neutrophils in Dendritic Cell-Based Cancer Vaccination: The Potential Roles of Neutrophil Extracellular Trap Formation
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-01-01 / JAMA Oncol 2023 Jan;9(1):112-121
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-01-01 / JAMA Oncol 2023 Jan;9(1):112-1212023-01-01 00:00:002023-05-30 16:23:26Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-12-23 / Neuro Oncol 2022 Dec;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-12-23 / Neuro Oncol 2022 Dec;2022-12-23 00:00:002022-12-23 00:00:00Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination (DCVax-L) in glioblastoma: breakthrough or fata morgana?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-12-12 / Front Immunol 2022;13:1080947
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-12-12 / Front Immunol 2022;13:10809472022-12-12 00:00:002022-12-12 00:00:00Derivation and external validation of dendritic cell-related gene signatures for predicting prognosis and immunotherapy efficacy in bladder urothelial carcinoma
